Publications by authors named "Mark Biagi"

Claim this Profile
C
Correction: Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections.
Mohammed Al Musawa, Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, Melanie Rae Schrack, Mark Biagi

Infect Dis Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protecting shorelines in Canadian Indigenous communities: Environmental challenges, policy interventions, and mitigation technologies.
Rezvan Iravani, Mark Biagi, Sonia Laforest, Kenneth Lee, Lisa Isaacman

Mar Pollut Bull· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes.
Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, Taylor Morrisette, Kyle C Molina, Mark Biagi

Microbiol Spectr· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections.
Mohammed Al Musawa, Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, Melanie Rae Schrack, Mark Biagi

Infect Dis Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study.
Kaylee E Caniff, Nicholas Rebold, Xhilda Xhemali, Nikki Tran, Taryn A Eubank, Mark Biagi

Open Forum Infect Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: A retrospective cohort study.
Zackery P Bulman, Lishan Cao, Brooke N Curry, Mark Biagi, Amanda Vivo

Int J Antimicrob Agents· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Race or Ethnicity With Extended-Spectrum Beta-Lactamase Production in : A Case Control Study.
Alice N Hemenway, Mark Biagi, Timothy F Murrey, Jiehuan Sun, Erica Osei-Badu

Open Forum Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
Nicholas Rebold, Sara Alosaimy, Jeffrey C Pearson, Brandon Dionne, Ahmad Taqi, Mark Biagi

Infect Dis Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022.
Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M Lagnf, Taylor Morrisette, Mark Biagi

Microbiol Spectr· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
Sara Alosaimy, Abdalhamid M Lagnf, Athena L V Hobbs, Musa Mubarez, Wesley D Kufel, Mark Biagi

Clin Infect Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii.
Sara Alosaimy, Taylor Morrisette, Abdalhamid M Lagnf, Leonor M Rojas, Madeline A King, Mark Biagi

Microbiol Spectr· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Co-Infection in a Stem Cell Transplant Patient.
Michael Pierce, Wendy Slipke, Mark Biagi

Antibiotics (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values.
Alesia Vialichka, Mark Biagi, Kevin Meyer, Tiffany Wu, Aisha Shajee

Microbiol Spectr· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales.
Mark Biagi, Michelle Lee, Tiffany Wu, Aisha Shajee, Shitalben Patel

Diagn Microbiol Infect Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.
Taylor Abbey, Alesia Vialichka, Michele Jurkovic, Mark Biagi, Eric Wenzler

Microbiol Spectr· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.
Nicholas Rebold, Taylor Morrisette, Abdalhamid M Lagnf, Sara Alosaimy, Dana Holger, Mark Biagi

Open Forum Infect Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
Michelle Lee, Taylor Abbey, Mark Biagi, Eric Wenzler

Diagn Microbiol Infect Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of trichomoniasis with tinidazole following desensitization in a patient allergic to metronidazole.
Mark Biagi, Wendy Slipke, Alexa Smalley, Geoffrey Tsaras

Int J STD AIDS· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a 51-hospital Chicagoland regional antibiogram and comparison to local hospital and national surveillance data.
David A Butler, Mark Biagi, Vikas Gupta, Sarah Wieczorkiewicz, Lisa Young

Infect Control Hosp Epidemiol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.
David A Butler, Mark Biagi, Xing Tan, Samah Qasmieh, Zackery P Bulman

Curr Infect Dis Rep· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of an HIV-trained clinical pharmacist intervention on error rates of antiretroviral and opportunistic infection medications in the inpatient setting.
Thomas D Chiampas, Mark J Biagi, Melissa E Badowski

Pharm Pract (Granada)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candidemia Secondary to Chronic Candiduria.
Mark J Biagi, Nathan P Wiederhold, Connie Gibas, Brian L Wickes, Victoria Lozano

Open Forum Infect Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia.
Mark Biagi, David Butler, Xing Tan, Samah Qasmieh, Eric Wenzler

Antibiotics (Basel)· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AUC-Based Monitoring of Vancomycin: Closing the Therapeutic Window.
Mark J Biagi, David A Butler, Eric Wenzler

J Appl Lab Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection.
Rodrigo M Burgos, Mark J Biagi, Keith A Rodvold, Larry H Danziger

Expert Opin Drug Metab Toxicol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis